Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep upregulates PD-(L)1 / PD-L2

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 30, 2024 5:44pm

137 Views

Post# 36289581

RE:RE:RE:RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2

In metastatic breast cancer for example, certain patients cannot tolerate, do not respond, or quickly relapse on ADC therapy. In these instances a combination of pelareiorep + immune checkpoint inhibitor + chemotherapy could very well be indicated.

It is for this reason that ONCY's CMO Thomas Heineman finally announced that ONCY will be targeting early mBC patients with pelareorep in a podcast on Pharma Focus. It would better if ONCY put out a press release with this decision to move to the treatment of early mBC patients.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec